Contrasting Organon & Co. (NYSE:OGN) and Spero Therapeutics (NASDAQ:SPRO)

Organon & Co. (NYSE:OGN) and Spero Therapeutics (NASDAQ:SPRO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and price targets for Organon & Co. and Spero Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2	5	0	0	1.71
Spero Therapeutics	0	3	1	0	2.25

Organon & Co. currently has a consensus price target of $11.40, indicating a potential downside of 16.70%. Spero Therapeutics has a consensus price target of $6.00, indicating a potential upside of 435.71%. Given Spero Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Spero Therapeutics is more favorable than Organon & Co..

Risk and Volatility

Organon & Co. has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Valuation and Earnings

This table compares Organon & Co. and Spero Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.13 billion	0.59	$187.00 million	$0.77	17.77
Spero Therapeutics	$66.80 million	0.98	$8.57 million	$0.11	10.18

Organon & Co. has higher revenue and earnings than Spero Therapeutics. Spero Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Organon & Co. and Spero Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Spero Therapeutics	24.90%	16.17%	12.57%

Institutional & Insider Ownership

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

About Spero Therapeutics

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.